Blood: Neusonocell mesh trap promotes immune thrombosis in patients with acute crying in COVID-19

Center point:inCOVID-19ARDS, the neutrophil mesh trap (NETs) causes micro
thrombosisformation through platelet-neutral granulocyte interactionThe new NET suppressor factor (nNIF) blocks THE NET induced by COVID-19 plasma and represents a potential therapeutic intervention for COVID-19Summary:, more than 10 millionhave been infected with COVID-19worldwide, with a wide range of clinical manifestations, from simple thrombosis to acute respiratory distress syndrome (ARDS) that requires ventilator supportNeusoroscos is a special structure formed by chromosomal dehesion after neutrophil necrosis or apoptosis, the cytoplasm membrane remains intact, can be fixed to kill pathogens, and can triggerimmunethrombosisMiddleton and others conducted a retrospective cohort study of PATIENTs with COVID-19 (n-33), comparing age and gender-matched non-COVID-19 patients (n-17) to study the correlation between the severity and progression of NET and COVID-19researchers tested plasma myelin peroxidase (MPO)-DNA complex (NET), platelet factor 4, RANTES, and some cytokines, and three CASES of NET and platelet sefactory in COVID-19 lung autopsies The researchers also evaluated the NETT formation of neutrophils in patients with COVID-19 and neutrophils in healthy humans incubated with COVID-19 plasma, as well as the ability to form NET in a closed COVID-19 plasma-induced by the new NET inhibitor (nNIF) increased plasma MPO-DNA complex in patients with cortify-19 patients with tracheal intubation and death outcomes The severity of the disease is directly related to the plasma MPO-DNA complex, with PaO2/FiO2 negatively correlated In NET and neutrolet-platelet-immersed pulmonary biopsy COVID-19, which contains microthrombosis, there was a significant increase in soluble cytokines that trigger EDT Finally, at in vitro initiation, COVID-19 neutrophils form too much NET, and THE NET formation triggered by COVID-19 plasma can be blocked by nNIF , NET-triggered immunothrombosis may partly explain the clinical manifestations before thrombosis in patients with COVID-19, and NETs may be a target for therapeutic interventions